Tim Davis
Regional Head, UK Primary Markets at London Stock Exchange Group
Tim Haines
Executive Partner at AbingworthTim has more than 30 years of international management experience in the life sciences industry in both public and private companies. During his time at Abingworth Tim has taken Chair and board roles in a number of companies including Astex, Fovea, GammaDelta Therapeutics, MEDIAN Technologies, PowderMed, Sientra, Scorpion, Venatorx and Adaptate Biotherapeutics.
Before joining Abingworth in 2005 he was Chief Executive of the Abingworth portfolio company, Astex Therapeutics. Tim was with Astex for over five years and was instrumental in establishing it as one of the leading UK biotechnology companies. Previously, Tim was Chief Executive of two divisions of the publicly-listed medical technology company, Datascope Corp. Prior to Datascope, he held a number of other senior management positions in the US and Europe, including CEO of Thackray Inc and General Manager Baxter UK. Tim has a BSc from Exeter University and an MBA from INSEAD. He is on the Investment Advisory Board of Oxford University Innovation and is a former Director of the BIA, the BVCA Venture Committee and sat on the Wellcome Trust / NHS Health Innovation Challenge Fund.
Patrik Frei
CEO of Venture Valuation
Jenny Bailey Cooper
CEO of Ferryx
Peter Dines
Managing Director of Mercia Ventures
Emma Thorp
Founder & Coach of Thorp CoachingEmma is the Founder of Thorp Coaching, where she empowers leaders to achieve their goals while staying true to purpose, connection, and joy. With decades of leadership experience, including roles as Chief Commercial Officer and founder of a successful consulting business.
As Co-Founder of the Diverse Directors Programme, Emma champions diversity in boardrooms, preparing underrepresented leaders for Non-Executive Director roles. Her nature-inspired, intuitive coaching approach helps leaders navigate challenges and develop winning mindsets. On the panel “The Humble CEO – What Makes a Winning Mindset”, Emma will explore fostering resilience, embracing humility, and unlocking purpose-led leadership.
James Fry
Partner - Head of Life Sciences at Mills and Reeve LLPJames is a partner at the law firm Mills & Reeve and heads the firm's life sciences sector. James is an experienced commercial and IP transactions lawyer with significant experience across the life sciences, including biotech, pharma and medical technologies. He regularly advises biotech and biopharma organisations on out-licensing and in-licensing transactions, broader partnering transactions, and on product development and commercialisation.
KIRAN GULATI
Director, Business Operations of New England Biolabs (UK)
Simon Bornschein
Founder & Chief Executive Officer of Coding Bio
Jacob Hurst
Co-Founder & Chief Technology Officer of EtcemblyJacob Hurst, is the co-founder and CTO of Etcembly. Within Etcembly he helped pioneer the informatics techniques that have resulted in Etcembly being the second company in the world to affinity enhance a TCR to pM level and the first company to do so entirely by informatics. He holds a PhD in Machine Learning, and has worked with biological data since 2002.
Jacob has worked as a scientific researcher at University College London and University of Oxford. and has co-authored over 50 scientific papers with a deep knowledge of antibodies and TCRs.
Damian Marron
Head of Biopharma at Treehill Partners Ltd
Jon Rees
Co-Founder & Senior Discovery Scientist of MitoRx Therapeutics
Nik Sharma
Co-Founder CEO of BioCorteX
Mihriban Tuna
CEO of ImmutrinMihriban is an executive leader with over 20 years’ experience in biologics drug development across biotech and pharma. She is currently CEO of Immutrin and Entrepreneur in Residence at Cambridge Innovation Capital.
Previously, Mihriban was Chief Scientific Officer at Adaptate Biotherapeutics (acquired by Takeda), Senior Vice President of Drug Discovery at F-star Therapeutics and an early employee at Domantis (acquired by GSK).
Mihriban holds a BSc in Biology from Middle East Technical University, a PhD in Biochemistry from University of Sussex and an EMBA from University of Cambridge Judge Business School.